EP
VERA icon

Essential Partners’s Vera Therapeutics VERA Stock Holding History

Essential Partners’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$215 Buy
5
+2
+67% +$75 ﹤0.01% 2625
2026
Q1 		$121 Buy
3
+1
+50% +$43 ﹤0.01% 2696
2025
Q4 		$101 Hold
2
– – ﹤0.01% 2552
2025
Q3 		$58 Buy
+2
New +$46 ﹤0.01% 2551

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Essential Partners's VERA Position: Q2 2026 in Review

Essential Partners increased its Vera Therapeutics (VERA) stake by 67% in Q2 2026, buying an estimated $75 and bringing the position to 5 shares worth $215. The position accounts for ﹤0.01% of the portfolio, ranked #2625.

Essential Partners first reported a position in VERA in Q3 2025 and has held it in 4 quarters since. 219 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Essential Partners held 5 shares of Vera Therapeutics worth $215 as of Q2 2026.
  • Essential Partners bought 2 Vera Therapeutics shares in Q2 2026, an estimated $75.
  • Vera Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2625 holding.
  • Essential Partners first reported a position in Vera Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 219 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.